/**
 * C\u00e1ncer Ginecol\u00f3gico | Gynecologic Cancer - Comprehensive Educational Content
 *
 * Covers cervical, ovarian, and uterine cancer screening, risk factors,
 * and clinical management from basic literacy through evidence-based
 * OB/GYN protocols. Spanish-first with English translations.
 */

import { EducationalContent } from '../types';

export const cancerGinecologicoGynecologicCancer: EducationalContent = {
  id: 'womens-health-cancer-ginecologico',
  type: 'condition',
  name: 'C\u00e1ncer Ginecol\u00f3gico | Gynecologic Cancer',
  nameEs: 'C\u00e1ncer Ginecol\u00f3gico',
  alternateNames: [
    'C\u00e1nceres del aparato reproductor femenino | Female reproductive cancers',
    'C\u00e1ncer cervical, ov\u00e1rico, uterino | Cervical, ovarian, uterine cancer',
  ],

  levels: {
    1: {
      level: 1,
      summary:
        'Los c\u00e1nceres ginecol\u00f3gicos afectan los \u00f3rganos reproductivos de la mujer; el c\u00e1ncer cervical se puede prevenir con la vacuna del VPH y detectar temprano con el Papanicolaou. | Gynecologic cancers affect women\u2019s reproductive organs; cervical cancer can be prevented with the HPV vaccine and detected early with the Pap smear.',
      explanation: `## \u00bfQu\u00e9 son los c\u00e1nceres ginecol\u00f3gicos? | What are gynecologic cancers?

Los c\u00e1nceres ginecol\u00f3gicos son c\u00e1nceres que empiezan en los \u00f3rganos reproductivos de la mujer. Los tres m\u00e1s comunes son: | Gynecologic cancers start in women\u2019s reproductive organs. The three most common are:

### 1. C\u00e1ncer cervical (del cuello del \u00fatero) | Cervical Cancer

- Causado por el virus del VPH (virus del papiloma humano) | Caused by HPV (human papillomavirus)
- **Se puede prevenir con la vacuna del VPH** | **Can be prevented with the HPV vaccine**
- Se detecta temprano con el **Papanicolaou** (Pap) | Detected early with the **Pap smear**
- La vacuna se recomienda entre los 9-26 a\u00f1os | Vaccine recommended between ages 9-26

### 2. C\u00e1ncer de ovario | Ovarian Cancer

- A veces llamado "el asesino silencioso" porque los s\u00edntomas son vagos al principio | Sometimes called "the silent killer" because symptoms are vague at first
- S\u00edntomas: hinchaz\u00f3n abdominal, sentirse llena r\u00e1pido, dolor p\u00e9lvico, orinar frecuentemente | Symptoms: abdominal bloating, feeling full quickly, pelvic pain, frequent urination
- No hay prueba de tamizaje efectiva para la poblaci\u00f3n general | There is no effective screening test for the general population

### 3. C\u00e1ncer de \u00fatero (endometrio) | Uterine (Endometrial) Cancer

- El c\u00e1ncer ginecol\u00f3gico m\u00e1s com\u00fan en pa\u00edses desarrollados | Most common gynecologic cancer in developed countries
- S\u00edntoma principal: **sangrado vaginal despu\u00e9s de la menopausia** | Main symptom: **vaginal bleeding after menopause**
- Se detecta en etapas tempranas generalmente | Usually detected in early stages

### C\u00f3mo protegerte | How to protect yourself

- **Vac\u00fanate contra el VPH** (para ti y tus hijos/hijas) | **Get the HPV vaccine** (for you and your children)
- **Hazte el Papanicolaou regularmente** | **Get regular Pap smears**
- **Reporta cualquier sangrado anormal** a tu doctor | **Report any abnormal bleeding** to your doctor
- **Conoce tu historia familiar** de c\u00e1ncer | **Know your family history** of cancer
- **No fumes** \u2013 el tabaco aumenta el riesgo de c\u00e1ncer cervical | **Don\u2019t smoke** \u2013 tobacco increases cervical cancer risk

### Se\u00f1ales de alarma \u2013 ve al doctor | Warning Signs \u2013 see your doctor

- Sangrado entre periodos o despu\u00e9s de la menopausia | Bleeding between periods or after menopause
- Sangrado despu\u00e9s de relaciones sexuales | Bleeding after sex
- Flujo vaginal con olor o color inusual | Vaginal discharge with unusual odor or color
- Dolor p\u00e9lvico persistente | Persistent pelvic pain
- Hinchaz\u00f3n abdominal que no se va | Abdominal bloating that won\u2019t go away
- P\u00e9rdida de peso sin explicaci\u00f3n | Unexplained weight loss`,
      keyTerms: [
        {
          term: 'C\u00e1ncer ginecol\u00f3gico | Gynecologic cancer',
          definition:
            'C\u00e1ncer que empieza en los \u00f3rganos reproductivos de la mujer. | Cancer that starts in women\u2019s reproductive organs.',
        },
        {
          term: 'VPH (Virus del Papiloma Humano) | HPV (Human Papillomavirus)',
          definition:
            'Virus que puede causar c\u00e1ncer cervical; se previene con vacuna. | Virus that can cause cervical cancer; prevented with a vaccine.',
        },
        {
          term: 'Papanicolaou (Pap) | Pap Smear',
          definition:
            'Prueba que busca c\u00e9lulas anormales en el cuello del \u00fatero. | Test that looks for abnormal cells in the cervix.',
        },
        {
          term: 'C\u00e9rvix (cuello del \u00fatero) | Cervix',
          definition:
            'La parte baja del \u00fatero que conecta con la vagina. | The lower part of the uterus that connects to the vagina.',
        },
        {
          term: 'Endometrio | Endometrium',
          definition:
            'El revestimiento interior del \u00fatero. | The inner lining of the uterus.',
        },
      ],
      analogies: [
        'La vacuna del VPH es como un escudo que protege tu cuello uterino del virus que puede causar c\u00e1ncer. | The HPV vaccine is like a shield that protects your cervix from the virus that can cause cancer.',
        'El Papanicolaou es como un chequeo de seguridad que detecta problemas antes de que se conviertan en algo grave. | The Pap smear is like a safety check that catches problems before they become serious.',
      ],
      examples: [
        'Sof\u00eda, de 25 a\u00f1os, se vacun\u00f3 contra el VPH a los 12. Su Papanicolaou sali\u00f3 normal. Ella est\u00e1 protegida contra los tipos de VPH m\u00e1s peligrosos. | Sofia, 25, got her HPV vaccine at age 12. Her Pap smear came back normal. She is protected against the most dangerous HPV types.',
        'Doña Marta, de 62 a\u00f1os, not\u00f3 un poco de sangrado vaginal. Fue al doctor inmediatamente porque sab\u00eda que cualquier sangrado despu\u00e9s de la menopausia necesita evaluaci\u00f3n. | Doña Marta, 62, noticed some vaginal bleeding. She went to the doctor immediately because she knew any bleeding after menopause needs evaluation.',
      ],
      patientCounselingPoints: [
        'La vacuna del VPH es segura y efectiva \u2013 puede prevenir hasta el 90% de los c\u00e1nceres cervicales. | The HPV vaccine is safe and effective \u2013 it can prevent up to 90% of cervical cancers.',
        'Cualquier sangrado despu\u00e9s de la menopausia necesita evaluaci\u00f3n m\u00e9dica. No lo ignores. | Any bleeding after menopause needs medical evaluation. Don\u2019t ignore it.',
        'Los ex\u00e1menes regulares salvan vidas. Hazte tu Papanicolaou seg\u00fan las recomendaciones de tu doctor. | Regular screening saves lives. Get your Pap smear according to your doctor\u2019s recommendations.',
      ],
    },

    2: {
      level: 2,
      summary:
        'El tamizaje de c\u00e1ncer cervical sigue gu\u00edas espec\u00edficas seg\u00fan edad (citolog\u00eda vs. prueba de VPH vs. co-testing); el c\u00e1ncer endometrial se presenta con sangrado postmenop\u00e1usico y requiere biopsia; el c\u00e1ncer de ovario se diagnostica tard\u00edamente por s\u00edntomas inespec\u00edficos. | Cervical cancer screening follows age-specific guidelines (cytology vs. HPV testing vs. co-testing); endometrial cancer presents with postmenopausal bleeding and requires biopsy; ovarian cancer is diagnosed late due to nonspecific symptoms.',
      explanation: `## C\u00e1ncer cervical: Tamizaje y prevenci\u00f3n | Cervical Cancer: Screening and Prevention

### Gu\u00edas de tamizaje (ASCCP/ACS 2020) | Screening Guidelines (ASCCP/ACS 2020)

| Edad | Age | Recomendaci\u00f3n | Recommendation |
|------|-----|----------------|----------------|
| < 21 | < 21 | No tamizaje | No screening |
| 21-24 | 21-24 | Citolog\u00eda cada 3 a\u00f1os (sin prueba de VPH) | Cytology every 3 years (no HPV test) |
| 25-65 | 25-65 | Prueba primaria de VPH cada 5 a\u00f1os (preferida por ACS) | Primary HPV test every 5 years (ACS preferred) |
| 25-65 | 25-65 | Co-testing (citolog\u00eda + VPH) cada 5 a\u00f1os (aceptable) | Co-testing (cytology + HPV) every 5 years (acceptable) |
| 25-65 | 25-65 | Citolog\u00eda sola cada 3 a\u00f1os (aceptable) | Cytology alone every 3 years (acceptable) |
| > 65 | > 65 | Suspender si tamizaje previo adecuado y negativo | Stop if adequate prior negative screening |

### Vacunaci\u00f3n contra el VPH | HPV Vaccination
- **Gardasil 9**: Protege contra 9 tipos de VPH (6, 11, 16, 18, 31, 33, 45, 52, 58) | Protects against 9 HPV types
- Edad recomendada: 9-12 a\u00f1os (serie de 2 dosis) | Recommended age: 9-12 years (2-dose series)
- 13-26 a\u00f1os: serie de 3 dosis | 13-26 years: 3-dose series
- Eficacia contra VPH 16/18: >95% | Efficacy against HPV 16/18: >95%

### Resultados anormales del Papanicolaou | Abnormal Pap Results
- **ASC-US**: C\u00e9lulas escamosas at\u00edpicas de significado indeterminado \u2192 prueba de VPH refleja | Atypical squamous cells of undetermined significance \u2192 reflex HPV test
- **LSIL**: Lesi\u00f3n escamosa intraepitelial de bajo grado \u2192 colposcop\u00eda | Low-grade squamous intraepithelial lesion \u2192 colposcopy
- **HSIL**: Lesi\u00f3n escamosa intraepitelial de alto grado \u2192 colposcop\u00eda urgente | High-grade squamous intraepithelial lesion \u2192 urgent colposcopy
- **AGC**: C\u00e9lulas glandulares at\u00edpicas \u2192 colposcop\u00eda + biopsia endometrial + biopsia endocervical | Atypical glandular cells \u2192 colposcopy + endometrial biopsy + endocervical biopsy

## C\u00e1ncer de endometrio | Endometrial Cancer

### Factores de riesgo | Risk Factors
- Obesidad (riesgo 2-4x mayor) | Obesity (2-4x higher risk)
- Diabetes mellitus tipo 2 | Type 2 diabetes mellitus
- Menopausia tard\u00eda | Late menopause
- Nuliparidad | Nulliparity
- S\u00edndrome de Lynch (2-60% de riesgo de por vida) | Lynch syndrome (2-60% lifetime risk)
- Terapia con tamoxifeno | Tamoxifen therapy
- Estr\u00f3geno sin oposici\u00f3n de progesterona | Unopposed estrogen

### Evaluaci\u00f3n del sangrado postmenop\u00e1usico | Postmenopausal Bleeding Evaluation
1. Ecograf\u00eda transvaginal: grosor endometrial | Transvaginal ultrasound: endometrial thickness
   - \u22644 mm: riesgo muy bajo de c\u00e1ncer (<1%) | \u22644 mm: very low cancer risk (<1%)
   - > 4 mm: requiere biopsia endometrial | > 4 mm: requires endometrial biopsy
2. Biopsia endometrial (Pipelle): sensibilidad 90-99% para c\u00e1ncer | Endometrial biopsy (Pipelle): 90-99% sensitivity for cancer

## C\u00e1ncer de ovario | Ovarian Cancer

### Presentaci\u00f3n cl\u00ednica | Clinical Presentation
Los s\u00edntomas son vagos y a menudo se confunden con problemas digestivos: | Symptoms are vague and often confused with digestive problems:
- Hinchaz\u00f3n persistente | Persistent bloating
- Dificultad para comer o sensaci\u00f3n de llenura r\u00e1pida | Difficulty eating or feeling full quickly
- Dolor p\u00e9lvico o abdominal | Pelvic or abdominal pain
- S\u00edntomas urinarios (urgencia, frecuencia) | Urinary symptoms (urgency, frequency)

### Tamizaje | Screening
- **No se recomienda** tamizaje rutinario en mujeres de riesgo promedio | Routine screening is **not recommended** in average-risk women
- Estudio PLCO y UKCTOCS: el tamizaje con CA-125 y ecograf\u00eda no redujo mortalidad y aument\u00f3 cirug\u00edas innecesarias | PLCO and UKCTOCS studies: screening with CA-125 and ultrasound did not reduce mortality and increased unnecessary surgeries
- **Excepci\u00f3n**: Mujeres con BRCA1/2 \u2192 considerar ecograf\u00eda + CA-125 cada 6 meses (o salpingo-ooforectom\u00eda reductora de riesgo) | **Exception**: Women with BRCA1/2 \u2192 consider ultrasound + CA-125 every 6 months (or risk-reducing salpingo-oophorectomy)`,
      keyTerms: [
        {
          term: 'ASC-US',
          definition:
            'C\u00e9lulas escamosas at\u00edpicas de significado indeterminado; resultado anormal leve del Papanicolaou. | Atypical squamous cells of undetermined significance; mild abnormal Pap result.',
        },
        {
          term: 'HSIL',
          definition:
            'Lesi\u00f3n escamosa intraepitelial de alto grado; c\u00e9lulas precancer\u00edgenas que necesitan evaluaci\u00f3n urgente. | High-grade squamous intraepithelial lesion; precancerous cells needing urgent evaluation.',
        },
        {
          term: 'Colposcop\u00eda | Colposcopy',
          definition:
            'Examen del cuello uterino con un microscopio especial para buscar \u00e1reas anormales. | Examination of the cervix with a special microscope to look for abnormal areas.',
        },
        {
          term: 'CA-125',
          definition:
            'Marcador tumoral en sangre que puede estar elevado en c\u00e1ncer de ovario (pero tambi\u00e9n en otras condiciones). | Blood tumor marker that can be elevated in ovarian cancer (but also in other conditions).',
        },
        {
          term: 'S\u00edndrome de Lynch | Lynch Syndrome',
          definition:
            'Condici\u00f3n hereditaria que aumenta el riesgo de c\u00e1ncer colorrectal y endometrial. | Hereditary condition that increases risk of colorectal and endometrial cancer.',
        },
      ],
      analogies: [
        'El Papanicolaou detecta c\u00e9lulas "sospechosas" como un guardia de seguridad que identifica personas que no deber\u00edan estar en el edificio antes de que causen problemas. | The Pap smear detects "suspicious" cells like a security guard who identifies people who shouldn\u2019t be in the building before they cause problems.',
      ],
      examples: [
        'Isabel, de 45 a\u00f1os, tuvo un resultado de ASC-US en su Papanicolaou. Le hicieron una prueba de VPH que sali\u00f3 negativa, as\u00ed que solo necesita repetir en 3 a\u00f1os. | Isabel, 45, had an ASC-US result on her Pap. Her HPV test was negative, so she only needs to repeat in 3 years.',
      ],
    },

    3: {
      level: 3,
      summary:
        'La oncolog\u00eda ginecol\u00f3gica incluye la comprensi\u00f3n de la carcinog\u00e9nesis cervical por VPH (tipos 16/18 de alto riesgo), la clasificaci\u00f3n dualistic del c\u00e1ncer endometrial (Tipo I estrog\u00e9nico vs. Tipo II no estrog\u00e9nico), y la clasificaci\u00f3n molecular del c\u00e1ncer de ovario (seroso de alto grado, endometrioide, mucinoso, c\u00e9lulas claras). | Gynecologic oncology includes understanding HPV-driven cervical carcinogenesis (high-risk types 16/18), the dualistic classification of endometrial cancer (Type I estrogenic vs. Type II non-estrogenic), and molecular classification of ovarian cancer (high-grade serous, endometrioid, mucinous, clear cell).',
      explanation: `## Carcinog\u00e9nesis cervical | Cervical Carcinogenesis

### Biolog\u00eda del VPH | HPV Biology
- VPH infecta c\u00e9lulas basales del epitelio escamoso a trav\u00e9s de microtraumas | HPV infects basal cells of squamous epithelium through microtrauma
- **Tipos de alto riesgo oncog\u00e9nico**: 16, 18, 31, 33, 45, 52, 58 | **High-risk oncogenic types**: 16, 18, 31, 33, 45, 52, 58
- VPH 16: Responsable de ~55% de c\u00e1ncer cervical | HPV 16: Responsible for ~55% of cervical cancer
- VPH 18: Responsable de ~15% (especialmente adenocarcinoma) | HPV 18: Responsible for ~15% (especially adenocarcinoma)

### Oncoprote\u00ednas virales | Viral Oncoproteins
- **E6**: Se une a p53 \u2192 degradaci\u00f3n por ubiquitina \u2192 p\u00e9rdida de apoptosis | **E6**: Binds p53 \u2192 ubiquitin degradation \u2192 loss of apoptosis
- **E7**: Se une a pRb \u2192 liberaci\u00f3n de E2F \u2192 proliferaci\u00f3n celular descontrolada | **E7**: Binds pRb \u2192 E2F release \u2192 uncontrolled cell proliferation
- La integraci\u00f3n del ADN viral al genoma del hu\u00e9sped es el paso cr\u00edtico de la progresi\u00f3n | Integration of viral DNA into host genome is the critical progression step

### Progresi\u00f3n de displasia a c\u00e1ncer | Dysplasia to Cancer Progression
- Infecci\u00f3n por VPH \u2192 CIN 1 (LSIL) \u2192 CIN 2/3 (HSIL) \u2192 Carcinoma invasor | HPV infection \u2192 CIN 1 (LSIL) \u2192 CIN 2/3 (HSIL) \u2192 Invasive carcinoma
- Proceso que toma 10-20 a\u00f1os generalmente | Process typically takes 10-20 years
- 60% de CIN 1 regresan espont\u00e1neamente | 60% of CIN 1 regress spontaneously
- 30-50% de CIN 3 progresan a c\u00e1ncer invasor sin tratamiento | 30-50% of CIN 3 progress to invasive cancer without treatment

## C\u00e1ncer endometrial: Clasificaci\u00f3n dual\u00edstica | Endometrial Cancer: Dualistic Classification

### Tipo I (Endometrioide) \u2013 80% | Type I (Endometrioid) \u2013 80%
- Estrog\u00e9nico-dependiente | Estrogen-dependent
- Asociado con hiperplasia endometrial | Associated with endometrial hyperplasia
- Grado 1-2 generalmente | Generally grade 1-2
- Mejor pron\u00f3stico | Better prognosis
- Mutaciones comunes: PTEN, PIK3CA, KRAS, microsatelital inestabilidad | Common mutations: PTEN, PIK3CA, KRAS, microsatellite instability

### Tipo II (No endometrioide) \u2013 20% | Type II (Non-endometrioid) \u2013 20%
- No estrog\u00e9nico-dependiente | Not estrogen-dependent
- Subtipos: seroso, c\u00e9lulas claras, carcinosarcoma | Subtypes: serous, clear cell, carcinosarcoma
- M\u00e1s agresivo, peor pron\u00f3stico | More aggressive, worse prognosis
- Mutaciones comunes: TP53 (seroso), HER2 (seroso) | Common mutations: TP53 (serous), HER2 (serous)

### Clasificaci\u00f3n molecular TCGA (ProMisE/TransPORTEC) | TCGA Molecular Classification
1. **POLE ultramutado**: Mejor pron\u00f3stico (puede evitar radioterapia adyuvante) | **POLE ultramutated**: Best prognosis (may avoid adjuvant radiation)
2. **MSI-H / dMMR**: Buen pron\u00f3stico, responde a inmunoterapia | **MSI-H / dMMR**: Good prognosis, responds to immunotherapy
3. **Sin perfil molecular espec\u00edfico (NSMP)**: Pron\u00f3stico intermedio | **No specific molecular profile (NSMP)**: Intermediate prognosis
4. **p53 anormal**: Peor pron\u00f3stico (corresponde a seroso) | **p53 abnormal**: Worst prognosis (corresponds to serous)

## C\u00e1ncer de ovario: Clasificaci\u00f3n y patog\u00e9nesis | Ovarian Cancer: Classification and Pathogenesis

### Subtipos histol\u00f3gicos | Histologic Subtypes

| Subtipo | Subtype | Frecuencia | Frequency | Origen | Origin | Mutaciones clave | Key mutations |
|---------|---------|-----------|-----------|--------|--------|-----------------|---------------|
| Seroso alto grado | High-grade serous | 70% | 70% | Trompa de Falopio (fimbrias) | Fallopian tube (fimbriae) | TP53 (96%), BRCA1/2 (25%) | TP53 (96%), BRCA1/2 (25%) |
| Endometrioide | Endometrioid | 10% | 10% | Endometriosis | Endometriosis | ARID1A, PIK3CA, PTEN | ARID1A, PIK3CA, PTEN |
| C\u00e9lulas claras | Clear cell | 10% | 10% | Endometriosis | Endometriosis | ARID1A, PIK3CA | ARID1A, PIK3CA |
| Mucinoso | Mucinous | 3% | 3% | Teratoma/Brenner | Teratoma/Brenner | KRAS, HER2 | KRAS, HER2 |
| Seroso bajo grado | Low-grade serous | 5% | 5% | Bordeline seroso | Serous borderline | KRAS, BRAF | KRAS, BRAF |

### Paradigma de la trompa de Falopio | Fallopian Tube Paradigm
- Evidencia creciente de que el c\u00e1ncer seroso de alto grado se origina en las fimbrias de la trompa | Growing evidence that high-grade serous cancer originates in tubal fimbriae
- STIC (carcinoma intraepitelial tubario seroso) como precursor | STIC (serous tubal intraepithelial carcinoma) as precursor
- Base de la salpingectom\u00eda oportunista como estrategia de reducci\u00f3n de riesgo | Basis for opportunistic salpingectomy as risk reduction strategy`,
      keyTerms: [
        {
          term: 'E6 y E7 | E6 and E7',
          definition:
            'Oncoprote\u00ednas del VPH que inactivan los supresores tumorales p53 y pRb respectivamente. | HPV oncoproteins that inactivate tumor suppressors p53 and pRb respectively.',
        },
        {
          term: 'CIN (Neoplasia intraepitelial cervical) | Cervical Intraepithelial Neoplasia',
          definition:
            'Cambios precancerosos del epitelio cervical clasificados en grados 1-3. | Precancerous changes of cervical epithelium classified in grades 1-3.',
        },
        {
          term: 'Clasificaci\u00f3n molecular TCGA | TCGA Molecular Classification',
          definition:
            'Cuatro subgrupos moleculares del c\u00e1ncer endometrial con implicaciones pron\u00f3sticas y terap\u00e9uticas. | Four molecular subgroups of endometrial cancer with prognostic and therapeutic implications.',
        },
        {
          term: 'STIC (Carcinoma intraepitelial tubario seroso) | Serous Tubal Intraepithelial Carcinoma',
          definition:
            'Lesi\u00f3n precursora del c\u00e1ncer seroso de alto grado de ovario, localizada en las fimbrias de la trompa. | Precursor lesion of high-grade serous ovarian cancer, located in the tubal fimbriae.',
        },
        {
          term: 'Salpingectom\u00eda oportunista | Opportunistic Salpingectomy',
          definition:
            'Extracci\u00f3n de las trompas de Falopio durante cirug\u00edas ginecol\u00f3gicas b\u00e9nignas como estrategia de reducci\u00f3n de riesgo de c\u00e1ncer de ovario. | Removal of fallopian tubes during benign gynecologic surgeries as ovarian cancer risk reduction strategy.',
        },
      ],
      analogies: [
        'Las oncoprote\u00ednas E6 y E7 del VPH son como saboteadores: E6 destruye al "guardaespalda" p53 que detiene c\u00e9lulas da\u00f1adas, y E7 rompe el "freno" pRb que controla la divisi\u00f3n celular. Sin guardia ni freno, las c\u00e9lulas se multiplican sin control. | HPV oncoproteins E6 and E7 are like saboteurs: E6 destroys the "bodyguard" p53 that stops damaged cells, and E7 breaks the "brake" pRb that controls cell division. Without guard or brake, cells multiply uncontrollably.',
      ],
      examples: [
        'Una paciente de 55 a\u00f1os con c\u00e1ncer endometrial grado 1 endometrioide con mutaci\u00f3n POLE: pron\u00f3stico excelente y puede evitar radioterapia adyuvante seg\u00fan la clasificaci\u00f3n molecular. | A 55-year-old patient with grade 1 endometrioid endometrial cancer with POLE mutation: excellent prognosis and may avoid adjuvant radiation per molecular classification.',
      ],
    },

    4: {
      level: 4,
      summary:
        'El manejo cl\u00ednico incluye algoritmos ASCCP de riesgo para manejo de citolog\u00eda/VPH anormales, estadificaci\u00f3n quir\u00fargica FIGO del c\u00e1ncer endometrial, y el paradigma de cirug\u00eda de citorreducci\u00f3n m\u00e1xima + quimioterapia basada en platino para c\u00e1ncer de ovario avanzado. | Clinical management includes ASCCP risk-based algorithms for abnormal cytology/HPV management, FIGO surgical staging of endometrial cancer, and the paradigm of maximal cytoreductive surgery + platinum-based chemotherapy for advanced ovarian cancer.',
      explanation: `## Algoritmos ASCCP 2019 de manejo basado en riesgo | ASCCP 2019 Risk-Based Management Algorithms

### Principio clave | Key Principle
El manejo se basa en el **riesgo de CIN 3+** estimado a partir de la historia completa de tamizaje, no solo del resultado actual. | Management is based on **CIN 3+ risk** estimated from complete screening history, not just the current result.

| Riesgo de CIN 3+ | CIN 3+ Risk | Acci\u00f3n | Action |
|-------------------|-------------|--------|--------|
| < 0.15% | < 0.15% | Retorno a tamizaje rutinario (5 a\u00f1os) | Return to routine screening (5 years) |
| 0.15 - 0.54% | 0.15 - 0.54% | Retorno en 1 a\u00f1o | Return in 1 year |
| 0.55 - 3.9% | 0.55 - 3.9% | Retorno en 1 a\u00f1o (o colposcop\u00eda) | Return in 1 year (or colposcopy) |
| 4 - 24% | 4 - 24% | Colposcop\u00eda | Colposcopy |
| 25 - 59% | 25 - 59% | Colposcop\u00eda o tratamiento (excisi\u00f3n) | Colposcopy or treatment (excision) |
| \u2265 60% | \u2265 60% | Tratamiento (LEEP/conizaci\u00f3n) o colposcop\u00eda | Treatment (LEEP/conization) or colposcopy |

### Manejo de CIN | CIN Management
- **CIN 1**: Observaci\u00f3n con seguimiento en 12 meses | Observation with 12-month follow-up
- **CIN 2**: En <25 a\u00f1os: observaci\u00f3n aceptable; en \u226525 a\u00f1os: tratar o observar | In <25 years: observation acceptable; \u226525 years: treat or observe
- **CIN 3**: Procedimiento escisional (LEEP o conizaci\u00f3n con bistur\u00ed fr\u00edo) | Excisional procedure (LEEP or cold knife conization)
- **AIS (Adenocarcinoma in situ)**: Conizaci\u00f3n con bistur\u00ed fr\u00edo con m\u00e1rgenes negativos + legrado endocervical | Cold knife conization with negative margins + endocervical curettage

## Estadificaci\u00f3n FIGO 2023 del c\u00e1ncer endometrial | FIGO 2023 Endometrial Cancer Staging

### Estadificaci\u00f3n quir\u00fargica | Surgical Staging
- Histerectom\u00eda total + salpingo-ooforectom\u00eda bilateral | Total hysterectomy + bilateral salpingo-oophorectomy
- Lavados peritoneales | Peritoneal washings
- Linfadenectom\u00eda p\u00e9lvica \u00b1 para-a\u00f3rtica (o ganglio centinela) | Pelvic \u00b1 para-aortic lymphadenectomy (or sentinel node)
- Omentectom\u00eda (en seroso/c\u00e9lulas claras) | Omentectomy (in serous/clear cell)

### Estadios simplificados | Simplified Stages
- **I**: Limitado al cuerpo uterino | Limited to uterine body
- **IA**: <50% invasi\u00f3n miometrial | <50% myometrial invasion
- **IB**: \u226550% invasi\u00f3n miometrial | \u226550% myometrial invasion
- **II**: Invasi\u00f3n del estroma cervical | Cervical stromal invasion
- **III**: Extensi\u00f3n local/regional | Local/regional extension
- **IV**: Invasi\u00f3n de vejiga/recto o met\u00e1stasis a distancia | Bladder/rectal invasion or distant metastasis

### Terapia adyuvante basada en clasificaci\u00f3n molecular | Molecular Classification-Based Adjuvant Therapy
- **POLE mutado**: Puede omitir adyuvancia en estadio I-II | May omit adjuvant in stage I-II
- **dMMR/MSI-H**: Inmunoterapia (pembrolizumab + lenvatinib en recurrente) | Immunotherapy (pembrolizumab + lenvatinib in recurrent)
- **p53 anormal**: Quimioterapia + radioterapia agresiva | Chemotherapy + aggressive radiation

## C\u00e1ncer de ovario: Manejo quir\u00fargico y m\u00e9dico | Ovarian Cancer: Surgical and Medical Management

### Cirug\u00eda de citorreducci\u00f3n \u00f3ptima | Optimal Cytoreductive Surgery
- Objetivo: enfermedad residual = 0 (R0) o < 1 cm | Goal: residual disease = 0 (R0) or < 1 cm
- Procedimientos: histerectom\u00eda, BSO, omentectom\u00eda, linfadenectom\u00eda, resecci\u00f3n peritoneal, esplenectom\u00eda, resecci\u00f3n diafragm\u00e1tica seg\u00fan necesidad | Procedures: hysterectomy, BSO, omentectomy, lymphadenectomy, peritoneal resection, splenectomy, diaphragmatic resection as needed
- La citorreducci\u00f3n a R0 es el factor pron\u00f3stico quir\u00fargico m\u00e1s importante | R0 cytoreduction is the most important surgical prognostic factor

### Quimioterapia est\u00e1ndar | Standard Chemotherapy
- **Primera l\u00ednea**: Carboplatino (AUC 5-6) + Paclitaxel 175 mg/m\u00b2 cada 3 semanas x 6 ciclos | **First-line**: Carboplatin (AUC 5-6) + Paclitaxel 175 mg/m\u00b2 every 3 weeks x 6 cycles
- **Con bevacizumab**: A\u00f1adir bevacizumab 15 mg/kg + mantenimiento en estadio III-IV suboptimal | **With bevacizumab**: Add bevacizumab 15 mg/kg + maintenance in stage III-IV suboptimal
- **Mantenimiento con inhibidores de PARP** en BRCA1/2 mutado: Olaparib 300 mg BID x 2 a\u00f1os (estudio SOLO-1) | **PARP inhibitor maintenance** in BRCA1/2 mutated: Olaparib 300 mg BID x 2 years (SOLO-1 study)

### NACT (Quimioterapia neoadyuvante) | NACT (Neoadjuvant Chemotherapy)
- Considerar en pacientes con enfermedad voluminosa que no lograr\u00edan R0 en cirug\u00eda primaria | Consider in patients with bulky disease who wouldn\u2019t achieve R0 in primary surgery
- 3 ciclos de carboplatino + paclitaxel \u2192 cirug\u00eda de intervalo \u2192 3 ciclos m\u00e1s | 3 cycles of carboplatin + paclitaxel \u2192 interval surgery \u2192 3 more cycles
- Estudios CHORUS y EORTC 55971: no inferioridad vs. cirug\u00eda primaria en pacientes seleccionados | CHORUS and EORTC 55971 trials: non-inferiority vs. primary surgery in selected patients`,
      keyTerms: [
        {
          term: 'LEEP (Procedimiento de escisi\u00f3n electroquir\u00fargica con asa)',
          definition:
            'Procedimiento que usa un asa el\u00e9ctrica para remover tejido anormal del c\u00e9rvix. | Procedure using an electrical loop to remove abnormal cervical tissue.',
        },
        {
          term: 'Citorreducci\u00f3n \u00f3ptima | Optimal Cytoreduction',
          definition:
            'Cirug\u00eda que logra enfermedad residual \u22641 cm; el factor pron\u00f3stico quir\u00fargico m\u00e1s importante en c\u00e1ncer de ovario. | Surgery achieving \u22641 cm residual disease; the most important surgical prognostic factor in ovarian cancer.',
        },
        {
          term: 'Inhibidores de PARP | PARP Inhibitors',
          definition:
            'F\u00e1rmacos que bloquean la reparaci\u00f3n del ADN en c\u00e9lulas con deficiencia de BRCA, causando letalidad sint\u00e9tica. | Drugs that block DNA repair in cells with BRCA deficiency, causing synthetic lethality.',
        },
        {
          term: 'Ganglio centinela | Sentinel Node',
          definition:
            'Primer ganglio linf\u00e1tico que recibe drenaje del tumor; su biopsia puede evitar linfadenectom\u00eda completa. | First lymph node receiving drainage from the tumor; its biopsy may avoid complete lymphadenectomy.',
        },
        {
          term: 'NACT (Quimioterapia neoadyuvante) | Neoadjuvant Chemotherapy',
          definition:
            'Quimioterapia administrada antes de la cirug\u00eda para reducir el volumen tumoral. | Chemotherapy given before surgery to reduce tumor volume.',
        },
      ],
      clinicalNotes:
        'Los algoritmos ASCCP 2019 se basan en tablas de riesgo acumulativo, no en reglas simples de resultado. La herramienta en l\u00ednea (asccp.org) es esencial para decisiones precisas. En c\u00e1ncer endometrial, la clasificaci\u00f3n molecular (TCGA/ProMisE) ahora modifica las decisiones de tratamiento adyuvante. En c\u00e1ncer de ovario, los inhibidores de PARP han cambiado el paradigma de mantenimiento, especialmente en pacientes BRCA+. | ASCCP 2019 algorithms are based on cumulative risk tables, not simple result rules. The online tool (asccp.org) is essential for precise decisions. In endometrial cancer, molecular classification (TCGA/ProMisE) now modifies adjuvant treatment decisions. In ovarian cancer, PARP inhibitors have changed the maintenance paradigm, especially in BRCA+ patients.',
    },

    5: {
      level: 5,
      summary:
        'Protocolos oncol\u00f3gicos ginecol\u00f3gicos avanzados incluyen inmunoterapia (pembrolizumab + lenvatinib) basada en biomarcadores en c\u00e1ncer endometrial, ensayos cl\u00ednicos de combinaci\u00f3n iPARP + antiangiog\u00e9nicos en c\u00e1ncer de ovario, estrategias de desescalada terap\u00e9utica en c\u00e1ncer cervical (SHAPE trial), y algoritmos de preservaci\u00f3n de fertilidad en c\u00e1nceres ginecol\u00f3gicos tempranos. | Advanced gynecologic oncology protocols include biomarker-based immunotherapy (pembrolizumab + lenvatinib) in endometrial cancer, iPARP + antiangiogenic combination trials in ovarian cancer, therapeutic de-escalation strategies in cervical cancer (SHAPE trial), and fertility preservation algorithms in early gynecologic cancers.',
      explanation: `## Inmunoterapia en c\u00e1ncer endometrial | Immunotherapy in Endometrial Cancer

### Algoritmo de selecci\u00f3n de terapia por biomarcadores | Biomarker-Based Therapy Selection Algorithm

**C\u00e1ncer endometrial avanzado/recurrente:** | **Advanced/recurrent endometrial cancer:**

| Biomarcador | Biomarker | Terapia | Therapy | Evidencia | Evidence |
|-------------|-----------|---------|---------|-----------|----------|
| dMMR/MSI-H | dMMR/MSI-H | Dostarlimab monoterapia | Dostarlimab monotherapy | GARNET (ORR 42%) |
| dMMR/MSI-H | dMMR/MSI-H | Pembrolizumab monoterapia | Pembrolizumab monotherapy | KEYNOTE-158 (ORR 48%) |
| pMMR/MSS | pMMR/MSS | Pembrolizumab + lenvatinib | Pembrolizumab + lenvatinib | KEYNOTE-775 (OS 18.3 vs 11.4 meses) |
| HER2+ (seroso) | HER2+ (serous) | Trastuzumab + quimio | Trastuzumab + chemo | DESTINY-PanTumor02 |
| p53 anormal | p53 abnormal | Quimio intensiva \u00b1 inmunoterapia | Intensive chemo \u00b1 immunotherapy | En investigaci\u00f3n |

### Ensayo RUBY (dostarlimab + carboplatino-paclitaxel) | RUBY Trial
- Primera l\u00ednea en c\u00e1ncer endometrial avanzado | First-line in advanced endometrial cancer
- dMMR: HR para PFS 0.28 (beneficio significativo) | dMMR: HR for PFS 0.28 (significant benefit)
- pMMR: HR para PFS 0.76 (beneficio m\u00e1s modesto) | pMMR: HR for PFS 0.76 (more modest benefit)
- Destaca la importancia de la testeo universal de MMR en c\u00e1ncer endometrial | Highlights importance of universal MMR testing in endometrial cancer

## Avances en c\u00e1ncer de ovario | Advances in Ovarian Cancer

### Estratificaci\u00f3n por estado de HRD | HRD Status Stratification

**Ensayos clave de inhibidores de PARP:** | **Key PARP Inhibitor Trials:**

| Estudio | Study | Poblaci\u00f3n | Population | PFS mediana (iPARP vs. control) | Median PFS |
|---------|-------|-----------|------------|-------------------------------|-----------|
| SOLO-1 | SOLO-1 | BRCA+ 1\u00aa l\u00ednea | BRCA+ 1st line | 56 vs. 13.8 meses (olaparib) | 56 vs. 13.8 months |
| PRIMA/ENGOT-OV26 | PRIMA | Todas, 1\u00aa l\u00ednea | All, 1st line | 13.8 vs. 8.2 (niraparib) | 13.8 vs. 8.2 |
| PAOLA-1 | PAOLA-1 | Todas + bevacizumab | All + bevacizumab | HRD+: 37.2 vs. 17.7 (olaparib) | HRD+: 37.2 vs. 17.7 |
| ATHENA-MONO | ATHENA | Todas, 1\u00aa l\u00ednea | All, 1st line | BRCA+: NR vs. 14.5 (rucaparib) | BRCA+: NR vs. 14.5 |

### Combinaciones emergentes | Emerging Combinations
- **iPARP + antiangiog\u00e9nicos** (olaparib + cediranib): Ensayos ICON9/GY004 | **iPARP + antiangiogenics**: ICON9/GY004 trials
- **iPARP + inmunoterapia** (niraparib + pembrolizumab): Ensayos FIRST/DUO-O | **iPARP + immunotherapy**: FIRST/DUO-O trials
- **Conjugados anticuerpo-droga (ADC)**: Mirvetuximab soravtansine (anti-FR\u03b1) aprobado FDA para FR\u03b1+ platino-resistente | **Antibody-drug conjugates (ADC)**: Mirvetuximab soravtansine (anti-FR\u03b1) FDA-approved for FR\u03b1+ platinum-resistant

## Desescalada terap\u00e9utica en c\u00e1ncer cervical | Therapeutic De-escalation in Cervical Cancer

### Ensayo SHAPE | SHAPE Trial
- C\u00e1ncer cervical de bajo riesgo estadio IA2-IB1 (\u22642 cm) | Low-risk cervical cancer stage IA2-IB1 (\u22642 cm)
- Conizaci\u00f3n/histerectom\u00eda simple vs. histerectom\u00eda radical | Conization/simple hysterectomy vs. radical hysterectomy
- Criterios de bajo riesgo: tumor \u22642 cm, invasi\u00f3n estromal <10 mm, sin LVSI extenso | Low-risk criteria: tumor \u22642 cm, stromal invasion <10 mm, without extensive LVSI
- Resultado: No inferioridad de la cirug\u00eda menos radical | Result: Non-inferiority of less radical surgery

### Preservaci\u00f3n de fertilidad en c\u00e1ncer cervical | Fertility Preservation in Cervical Cancer
- **Traquelectom\u00eda radical**: Remueve c\u00e9rvix + parametrios, preserva cuerpo uterino | **Radical trachelectomy**: Removes cervix + parametria, preserves uterine body
- Elegibilidad: estadio IA1 con LVSI a IB1 (\u22642 cm), sin invasi\u00f3n ganglionar | Eligibility: stage IA1 with LVSI to IB1 (\u22642 cm), no nodal involvement
- Tasa de embarazo post-traquelectom\u00eda: 50-70% (pero 25% parto prematuro) | Post-trachelectomy pregnancy rate: 50-70% (but 25% preterm delivery)
- Evaluaci\u00f3n ganglionar laparosc\u00f3pica previa obligatoria (ganglio centinela) | Mandatory prior laparoscopic nodal assessment (sentinel node)

## Tamizaje en poblaciones especiales | Screening in Special Populations

### S\u00edndrome de Lynch y c\u00e1ncer endometrial | Lynch Syndrome and Endometrial Cancer
- Riesgo de c\u00e1ncer endometrial: 40-60% de por vida | Lifetime endometrial cancer risk: 40-60%
- Tamizaje: Biopsia endometrial anual desde los 30-35 a\u00f1os | Screening: Annual endometrial biopsy from age 30-35
- Histerectom\u00eda + BSO profilаctica al completar paridad | Prophylactic hysterectomy + BSO when childbearing complete
- Testeo universal de MMR/MSI en todo c\u00e1ncer endometrial (NCCN) | Universal MMR/MSI testing in all endometrial cancer (NCCN)

### BRCA1/2 y c\u00e1ncer de ovario | BRCA1/2 and Ovarian Cancer
- BRCA1: Riesgo ov\u00e1rico 39-46% de por vida | BRCA1: 39-46% lifetime ovarian risk
- BRCA2: Riesgo ov\u00e1rico 10-27% de por vida | BRCA2: 10-27% lifetime ovarian risk
- Salpingo-ooforectom\u00eda reductora de riesgo recomendada a los 35-40 a\u00f1os (BRCA1) o 40-45 (BRCA2) | Risk-reducing salpingo-oophorectomy recommended at 35-40 years (BRCA1) or 40-45 (BRCA2)
- Testeo universal de BRCA en todo c\u00e1ncer epitelial de ovario (NCCN) | Universal BRCA testing in all epithelial ovarian cancer (NCCN)`,
      keyTerms: [
        {
          term: 'Letalidad sint\u00e9tica | Synthetic Lethality',
          definition:
            'Principio de los inhibidores de PARP: las c\u00e9lulas con deficiencia de BRCA dependen de PARP para reparar ADN; al inhibir PARP, la c\u00e9lula tumoral muere. | Principle of PARP inhibitors: cells with BRCA deficiency depend on PARP for DNA repair; by inhibiting PARP, the tumor cell dies.',
        },
        {
          term: 'HRD (Deficiencia de recombinaci\u00f3n hom\u00f3loga) | Homologous Recombination Deficiency',
          definition:
            'Biomarcador que predice respuesta a inhibidores de PARP; incluye mutaciones BRCA1/2 y otras alteraciones de la v\u00eda de reparaci\u00f3n del ADN. | Biomarker predicting response to PARP inhibitors; includes BRCA1/2 mutations and other DNA repair pathway alterations.',
        },
        {
          term: 'Mirvetuximab soravtansine',
          definition:
            'Conjugado anticuerpo-droga dirigido al receptor de folato alfa (FR\u03b1) aprobado para c\u00e1ncer de ovario platino-resistente. | Antibody-drug conjugate targeting folate receptor alpha (FR\u03b1) approved for platinum-resistant ovarian cancer.',
        },
        {
          term: 'Traquelectom\u00eda radical | Radical Trachelectomy',
          definition:
            'Cirug\u00eda que preserva la fertilidad removiendo el c\u00e9rvix y parametrios pero conservando el cuerpo uterino. | Fertility-preserving surgery removing the cervix and parametria but conserving the uterine body.',
        },
        {
          term: 'dMMR/MSI-H',
          definition:
            'Deficiencia en reparaci\u00f3n de apareamientos err\u00f3neos/inestabilidad de microsat\u00e9lites alta: biomarcador de respuesta a inmunoterapia. | Mismatch repair deficiency/high microsatellite instability: biomarker of immunotherapy response.',
        },
      ],
      clinicalNotes:
        'El testeo universal de MMR/MSI es ahora est\u00e1ndar de cuidado en todo c\u00e1ncer endometrial (identifica Lynch y predice respuesta a inmunoterapia). En c\u00e1ncer de ovario, el testeo de BRCA y HRD es obligatorio para guiar la terapia de mantenimiento con iPARP. La desescalada quir\u00fargica (SHAPE) cambia el paradigma de c\u00e1ncer cervical temprano de bajo riesgo. El ensayo RUBY establece la combinaci\u00f3n dostarlimab + quimioterapia como nuevo est\u00e1ndar en c\u00e1ncer endometrial avanzado dMMR. | Universal MMR/MSI testing is now standard of care in all endometrial cancer (identifies Lynch and predicts immunotherapy response). In ovarian cancer, BRCA and HRD testing is mandatory to guide iPARP maintenance therapy. Surgical de-escalation (SHAPE) changes the paradigm for low-risk early cervical cancer. The RUBY trial establishes dostarlimab + chemotherapy as the new standard in dMMR advanced endometrial cancer.',
    },
  },

  media: [],

  citations: [
    {
      id: 'cit-gyncancer-asccp-2019',
      type: 'guideline',
      title: '2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors',
      authors: ['Perkins, R.B.', 'Guido, R.S.'],
      source: 'Journal of Lower Genital Tract Disease',
      url: 'https://www.asccp.org/management-guidelines',
    },
    {
      id: 'cit-gyncancer-nccn-cervical',
      type: 'guideline',
      title: 'NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer',
      source: 'National Comprehensive Cancer Network',
      url: 'https://www.nccn.org/professionals/physician_gls/default.aspx',
    },
    {
      id: 'cit-gyncancer-solo1',
      type: 'journal',
      title: 'Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer (SOLO-1)',
      authors: ['Moore, K.', 'Colombo, N.'],
      source: 'New England Journal of Medicine',
      page: '379:2495-2505',
    },
    {
      id: 'cit-gyncancer-keynote775',
      type: 'journal',
      title: 'Lenvatinib plus Pembrolizumab in Advanced Endometrial Cancer (KEYNOTE-775)',
      authors: ['Makker, V.'],
      source: 'New England Journal of Medicine',
      page: '386:437-448',
    },
    {
      id: 'cit-gyncancer-shape',
      type: 'journal',
      title: 'Simple Hysterectomy and Pelvic Node Assessment for Low-Risk Cervical Cancer (SHAPE)',
      authors: ['Plante, M.'],
      source: 'New England Journal of Medicine',
    },
    {
      id: 'cit-gyncancer-ruby',
      type: 'journal',
      title: 'Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY)',
      authors: ['Mirza, M.R.'],
      source: 'New England Journal of Medicine',
      page: '388:2145-2158',
    },
    {
      id: 'cit-gyncancer-tcga-endometrial',
      type: 'journal',
      title: 'Integrated Genomic Characterization of Endometrial Carcinoma (TCGA)',
      source: 'Nature',
      page: '497:67-73',
    },
  ],

  crossReferences: [
    {
      targetId: 'womens-health-ciclo-menstrual-menstrual-cycle',
      targetType: 'process',
      relationship: 'related',
      label: 'Ciclo menstrual | Menstrual Cycle',
    },
    {
      targetId: 'womens-health-menopausia-menopause',
      targetType: 'process',
      relationship: 'related',
      label: 'Menopausia | Menopause',
    },
    {
      targetId: 'womens-health-salud-mamaria-breast-health',
      targetType: 'topic',
      relationship: 'sibling',
      label: 'Salud mamaria | Breast Health',
    },
    {
      targetId: 'womens-health-embarazo-pregnancy',
      targetType: 'process',
      relationship: 'see-also',
      label: 'Embarazo | Pregnancy',
    },
  ],

  tags: {
    systems: ['reproductive'],
    topics: ['gynecologic-oncology', 'screening', 'immunotherapy', 'womens-health'],
    keywords: [
      'c\u00e1ncer cervical',
      'cervical cancer',
      'VPH',
      'HPV',
      'c\u00e1ncer endometrial',
      'endometrial cancer',
      'c\u00e1ncer de ovario',
      'ovarian cancer',
      'Papanicolaou',
      'Pap smear',
      'BRCA',
      'inhibidores de PARP',
      'PARP inhibitors',
      'inmunoterapia',
      'immunotherapy',
      'tamizaje',
      'screening',
    ],
    clinicalRelevance: 'critical',
    examRelevance: {
      usmle: true,
      nbme: true,
      shelf: ['obstetrics-gynecology'],
    },
  },

  createdAt: '2025-06-01',
  updatedAt: '2025-06-01',
  version: 1,
  status: 'published',
  contributors: ['SOMA Medical Education Team'],
};
